Revenue during the quarter grew 21.99 percent to $53.06 million from $43.49 million in the previous year period. Gross margin for the quarter expanded 139 basis points over the previous year period to 61.95 percent. Total expenses were 90.64 percent of quarterly revenues, down from 93.09 percent for the same period last year. This has led to an improvement of 245 basis points in operating margin to 9.36 percent.

Operating income for the quarter was $4.97 million, compared with $3.01 million in the previous year period.

However, the adjusted operating income for the quarter stood at $7.36 million compared to $4.40 million in the prior year period. At the same time, adjusted operating margin improved 377 basis points in the quarter to 13.88 percent from 10.11 percent in the last year period.

Joseph H. Capper, president and chief executive officer of BioTelemetry, Inc., commented: "With our strong third quarter results, we delivered our seventeenth consecutive quarter of year over year revenue growth and our seventh consecutive quarter of year over year net income growth. Our commitment to our core operating principles continues to deliver outstanding results, as evidenced by our 40% adjusted EBITDA growth. Our top line momentum, with 22% growth, was driven by the success of our sales strategy to be the single source provider of cardiac monitoring solutions. As a result, we continue to grow substantially faster than the market, posting 9% patient volume growth, highlighted by double digit MCT growth. Additionally, our second quarter acquisitions had a positive impact on both our top and bottom lines."